Noor Ul Ain Rehman
Sat, January 10, 2026 astatine 1:57 PM CST 2 min read
56.2% of patients who received Saphnelo successful the TULIP-SC afloat investigation showed illness enactment simplification astatine Week 52 compared to 37.1% receiving placebo, arsenic measured by the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA), with the results accordant with those from erstwhile trials.
Management further reported that the information illustration observed successful the TULIP-SC proceedings was besides accordant with Saphnelo’s known objective profile, administered arsenic an intravenous (IV) infusion. According to AstraZeneca PLC (NASDAQ:AZN), the afloat results corroborated the findings from the interim analysis, which was statistically significant.
AstraZeneca PLC (NASDAQ:AZN) is simply a biopharmaceutical institution that explores, develops, manufactures, and commercializes medicine medicines. It supplies its products and services to specialty and superior attraction physicians.
While we admit the imaginable of AZN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This nonfiction is primitively published at Insider Monkey.

2 days ago
2






English (CA) ·
English (US) ·
Spanish (MX) ·